Drug intelligence / Profile preview

SGT003

Development stage: Preclinical
Lead developer: Hotgen Biotech
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SGT003 is an innovative bispecific antibody developed by Sungen Biomedical, a subsidiary of Hotgen Biotech, for the treatment of solid tumors. The drug is designed to target Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) with a specific mechanism of action aimed at selectively depleting regulatory T cells (Tregs) within the tumor microenvironment. By reducing the immunosuppressive activity of Tregs, SGT003 seeks to enhance the body's anti-tumor immune response. Preclinical results presented at the 2026 JPM Focus Series indicate that SGT003 may offer advantages over existing anti-PD-1 and anti-CTLA-4 therapies. It is currently in the preclinical stage of development and was developed using Sungen's proprietary CTLA-4 dual-target innovative platform.

Other names: SGT003 (Innovative Bispecific Antibody for Tumor Immunotherapy)

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on SGT003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGT003.

Explore the full profile